Web-hosted Engine for Continuously Improving the Identification of Safer Products for Administration
AssigneeBioInventors & Entrepreneurs Network, LLC
InventorMichael Seul
Life of this patent
Estimating the term…
Abstract
Genetic information relating to clinically significant attributes are generated as unique molecular signatures, which are provided to a subscriber to be carried as a card or in another form, including for display by a subscriber's computer or smart-phone or PDA. The signature is periodically updated as new clinically significant attributes become known. The process of updating the signature and using it to obtain suitable products (which don't have an unacceptable risk of generating an adverse reaction or outcome) is also described.
Claims21
A process for improving the identification and administration of safer products, including cells and cell-derived products for administration to subscribers, such that the products identified entail a lower risk of adverse reactions or adverse outcomes when administered to a subscriber, wherein the process accommodates additional clinically significant attributes, once these are determined to be significant, comprising the following steps:
- a. storing a unique subscriber identifier in a device controlled by the subscriber;
- b. generating and updating an encrypted molecular signature for the subscriber by:
- b1. encrypting several of the subscriber's clinically significant molecular attributes which are known to be associated with adverse reactions or adverse clinical outcomes as a first encrypted subscriber molecular signature;
- b2. providing sending the first encrypted molecular signature to the device whereby the first encrypted molecular signature is stored in the device to the subscriber;
- b3. identifying additional clinically significant molecular attributes that are to be added to the first molecular signature;
- b4. encrypting all the subscriber's clinically significant molecular attributes as a new molecular signature and sending it to the device whereby storing the new molecular signature is stored in the device;
- b5. repeating steps b1 to b4 as other additional clinically significant attributes are identified;
- c. receiving or obtaining the profile of the clinically significant attributes of candidate products to be administered to the subscriber;
- and
- d. analyzing the similarities and differences between the subscriber's molecular signature and the profile of the products to be administered to said subscriber, and administering products which either:
- do not contain any clinically significant attributes which the subscriber does not also express;
- or
- contain some clinically significant attributes which the subscriber does not express but said some clinically significant attributes do not render the product unacceptably unsafe based on the anticipated severity of the adverse subscriber reaction or adverse clinical outcome.
(canceled)
A process for improving the identification and administration of safer products, including cells and cell-derived products for administration to subscribers, such that the products identified entail a lower risk of adverse reactions or adverse outcomes when administered to a subscriber, wherein the process accommodates additional clinically significant attributes, once these are determined to be significant, comprising the following steps:
- a. storing a unique subscriber identifier in a device controlled by the subscriber;
- b. generating and updating an encrypted molecular signature for the subscriber by:
- b1. amplifying using a polymerase chain reaction portions of a subscriber's genome incorporating the subscriber's clinically significant molecular attributes;
- b2. encrypting several of the subscriber's clinically significant molecular attributes which are known to be associated with adverse reactions or adverse clinical outcomes as a first encrypted subscriber molecular signature;
- b3. sending the first encrypted molecular signature to the device whereby the first encrypted molecular signature is stored in the device;
- b4. identifying additional clinically significant molecular attributes that are to be added to the first molecular signature;
- b5. encrypting all the subscriber's clinically significant molecular attributes as a new molecular signature and sending it to the device whereby the new molecular signature is stored in the device;
- and
- b6. repeating steps b2 to b4 as other additional clinically significant attributes are identified;
- c. receiving or obtaining the profile of the clinically significant attributes of candidate products to be administered to the subscriber;
- and
- d. analyzing the similarities and differences between the subscriber's molecular signature and the profile of the products to be administered to said subscriber, and administering products which either:
- do not contain any clinically significant attributes which the subscriber does not also express;
- or
- contain some clinically significant attributes which the subscriber does not express but said some clinically significant attributes do not render the product unacceptably unsafe based on the anticipated severity of the adverse subscriber reaction or adverse clinical outcome.
Dependencies are inferred from the claim text.